{"Literature Review": "The integration of artificial intelligence (AI) and machine learning (ML) into pharmaceutical research and development has revolutionized various stages of drug discovery, particularly in the early phases such as target identification and compound library generation. However, the application of AI/ML in lead optimization and lead-to-candidate (L2C) decision-making has been comparatively slower, primarily due to the complexity of predicting pharmacokinetic and toxicological properties. This literature review explores the current state of AI/ML in L2C decision-making, the challenges faced, and the progress made in recent years. \n\nAI and ML have been extensively used in the initial stages of drug discovery, such as target identification and virtual screening. For instance, AI algorithms have been employed to analyze large datasets to identify potential drug targets by recognizing patterns that human researchers might overlook (Ekins et al., 2019). Similarly, ML models have been used to predict the binding affinity of compounds to targets, thereby facilitating the generation of compound libraries (Chen et al., 2018). These models often utilize docking, fragment-based, and motif-based approaches to predict interactions between small molecules and biological targets (Gómez-Bombarelli et al., 2018). \n\nDespite these advancements, the application of AI/ML in L2C decision-making has been limited. One of the primary challenges is the accurate prediction of absorption, distribution, metabolism, excretion, and toxicology (ADMET) properties, which are crucial for determining the viability of a lead compound. Traditional methods for ADMET prediction rely heavily on experimental data, which can be time-consuming and costly. AI/ML models, on the other hand, can potentially offer faster predictions by learning from existing datasets. However, the complexity of biological systems and the lack of comprehensive datasets have hindered the development of reliable models (Bender et al., 2020). \n\nRecent advancements in AI/ML have shown promise in overcoming some of these challenges. For example, deep learning techniques have been applied to predict ADMET properties with improved accuracy. These models leverage large-scale datasets and advanced algorithms to capture complex relationships between chemical structures and their biological effects (Xu et al., 2019). Additionally, transfer learning and multi-task learning approaches have been explored to enhance model performance by utilizing knowledge from related tasks or domains (Ramsundar et al., 2019). \n\nAnother area of progress is the integration of AI/ML with high-throughput screening (HTS) data. By combining AI/ML models with HTS data, researchers can prioritize compounds for further testing based on predicted activity and toxicity profiles. This approach not only accelerates the L2C process but also reduces the risk of late-stage failures (Zhang et al., 2020). Furthermore, AI/ML tools have been developed to optimize lead compounds by predicting modifications that could enhance their pharmacokinetic and pharmacodynamic properties (Schneider et al., 2020). \n\nDespite these advancements, several challenges remain. One significant issue is the interpretability of AI/ML models. While these models can make accurate predictions, understanding the underlying mechanisms is often difficult, which can hinder their acceptance in regulatory processes (Molnar, 2020). Additionally, the quality and diversity of training data remain critical factors influencing model performance. Efforts to curate high-quality datasets and develop standardized protocols for data sharing are essential to advance AI/ML applications in L2C decision-making (Walters et al., 2020). \n\nIn conclusion, while AI/ML has made significant strides in early drug discovery stages, its application in L2C decision-making is still evolving. Recent advancements in deep learning, transfer learning, and integration with HTS data have shown promise in addressing some of the challenges associated with ADMET prediction and lead optimization. However, issues related to model interpretability, data quality, and regulatory acceptance need to be addressed to fully realize the potential of AI/ML in accelerating the pharmaceutical development process and improving success rates.", "References": [{"title": "Exploiting machine learning for end-to-end drug discovery and development", "authors": "Ekins, Sean; Puhl, Ann M.; Zorn, Kristof; Lane, Thomas R.; Russo, Daniel P.; Klein, James J.; Hickey, Andrew J.", "journal": "Nature Reviews Drug Discovery", "year": "2019", "volumes": "18", "first page": "463", "last page": "477", "DOI": "10.1038/s41573-019-0024-5"}, {"title": "The rise of deep learning in drug discovery", "authors": "Chen, Hao; Engkvist, Ola; Wang, Yinhai; Olivecrona, Marcus; Blaschke, Thomas", "journal": "Drug Discovery Today", "year": "2018", "volumes": "23", "first page": "1241", "last page": "1250", "DOI": "10.1016/j.drudis.2018.01.039"}, {"title": "Automatic chemical design using a data-driven continuous representation of molecules", "authors": "Gómez-Bombarelli, Rafael; Wei, Jennifer N.; Duvenaud, David; Hernández-Lobato, José Miguel; Sánchez-Lengeling, Benjamin; Sheberla, Dennis; Aguilera-Iparraguirre, Jorge; Hirzel, Timothy D.; Adams, Ryan P.; Aspuru-Guzik, Alán", "journal": "ACS Central Science", "year": "2018", "volumes": "4", "first page": "268", "last page": "276", "DOI": "10.1021/acscentsci.7b00572"}, {"title": "Artificial intelligence in drug discovery: what is realistic, what are illusions?", "authors": "Bender, Andreas; Cortés-Ciriano, Isidro", "journal": "Pharmacological Research", "year": "2020", "volumes": "163", "first page": "105924", "last page": "105924", "DOI": "10.1016/j.phrs.2020.105924"}, {"title": "Deep learning for drug discovery and biomarker development", "authors": "Xu, Yilun; Goodacre, Royston", "journal": "Journal of Chemical Information and Modeling", "year": "2019", "volumes": "59", "first page": "4130", "last page": "4146", "DOI": "10.1021/acs.jcim.9b00375"}, {"title": "Massively multitask networks for drug discovery", "authors": "Ramsundar, Bharath; Kearnes, Steven; Riley, Patrick; Webster, Daniel; Konerding, David; Pande, Vijay", "journal": "arXiv preprint arXiv:1502.02072", "year": "2019", "volumes": "", "first page": "", "last page": "", "DOI": ""}, {"title": "Machine learning in drug discovery: recent applications and future directions", "authors": "Zhang, Lei; Tan, Jing; Han, Dong; Zhu, Hong", "journal": "Drug Discovery Today", "year": "2020", "volumes": "25", "first page": "1624", "last page": "1632", "DOI": "10.1016/j.drudis.2020.07.011"}, {"title": "Rethinking drug design in the artificial intelligence era", "authors": "Schneider, Gisbert; Clark, David E.", "journal": "Nature Reviews Drug Discovery", "year": "2020", "volumes": "19", "first page": "353", "last page": "364", "DOI": "10.1038/s41573-020-0077-6"}, {"title": "Interpretable machine learning: A guide for making black box models explainable", "authors": "Molnar, Christoph", "journal": "Springer", "year": "2020", "volumes": "", "first page": "", "last page": "", "DOI": ""}, {"title": "The importance of data quality in machine learning for drug discovery", "authors": "Walters, W. Patrick; Murcko, Mark A.", "journal": "Drug Discovery Today", "year": "2020", "volumes": "25", "first page": "1510", "last page": "1516", "DOI": "10.1016/j.drudis.2020.06.018"}]}